Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).
Jódar E, Michelsen M, Polonsky W, Réa R, Sandberg A, Vilsbøll T, Warren M, Harring S, Ziegler U, Bain S. Jódar E, et al. Among authors: harring s. Diabetes Obes Metab. 2020 Aug;22(8):1339-1347. doi: 10.1111/dom.14039. Epub 2020 Apr 27. Diabetes Obes Metab. 2020. PMID: 32227613 Free PMC article. Clinical Trial.
Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
Schou M, Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Patel S, Chinnakondepalli KM, Harring S, Abildstrøm SZ, Liisberg K, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Schou M, et al. Among authors: harring s. J Am Coll Cardiol. 2024 Jul 16;84(3):247-257. doi: 10.1016/j.jacc.2024.04.038. Epub 2024 Jun 23. J Am Coll Cardiol. 2024. PMID: 38913004 Free article. Clinical Trial.
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN; STEP-HFpEF Trials Committees and Investigators. Davies MJ, et al. Among authors: harring s. Lancet Diabetes Endocrinol. 2025 Jan 20:S2213-8587(24)00304-8. doi: 10.1016/S2213-8587(24)00304-8. Online ahead of print. Lancet Diabetes Endocrinol. 2025. PMID: 39848268
Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy.
Kraxner A, Braun F, Cheng WY, Yang TO, Pipaliya S, Canamero M, Andersson E, Harring SV, Dziadek S, Bröske AE, Ceppi M, Tanos T, Teichgräber V, Charo J. Kraxner A, et al. Among authors: harring sv. Front Immunol. 2024 Jul 5;15:1352632. doi: 10.3389/fimmu.2024.1352632. eCollection 2024. Front Immunol. 2024. PMID: 39035007 Free PMC article.
Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies.
Dziadek S, Kraxner A, Cheng WY, Ou Yang TH, Flores M, Theiss N, Tsao TS, Andersson E, Harring SV, Bröske AE, Ceppi M, Teichgräber V, Charo J. Dziadek S, et al. Among authors: harring sv. Front Immunol. 2024 Mar 15;15:1352615. doi: 10.3389/fimmu.2024.1352615. eCollection 2024. Front Immunol. 2024. PMID: 38558814 Free PMC article.
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies.
Heil F, Babitzki G, Julien-Laferriere A, Ooi CH, Hidalgo M, Massard C, Martinez-Garcia M, Le Tourneau C, Kockx M, Gerber P, Rossomanno S, Krieter O, Lahr A, Wild N, Harring SV, Lechner K. Heil F, et al. Among authors: harring sv. Transl Oncol. 2021 Feb;14(2):100984. doi: 10.1016/j.tranon.2020.100984. Epub 2020 Dec 15. Transl Oncol. 2021. PMID: 33338877 Free PMC article.
Dual-Energy CT Material Density Iodine Quantification for Distinguishing Vascular From Nonvascular Renal Lesions: Normalization Reduces Intermanufacturer Threshold Variability.
Patel BN, Vernuccio F, Meyer M, Godwin B, Rosenberg M, Rudnick N, Harring S, Nelson R, Ramirez-Giraldo JC, Farjat A, Marin D. Patel BN, et al. Among authors: harring s. AJR Am J Roentgenol. 2019 Feb;212(2):366-376. doi: 10.2214/AJR.18.20115. AJR Am J Roentgenol. 2019. PMID: 30667306
16 results